Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphans Dominate Products Seeking End-Of-Year Joy From CHMP

Executive Summary

Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.

Advertisement

Related Content

FDA's NDA And BLA Approvals: Lonhala Magnair, Ozempic
TiGenix CEO Confident Of European Green Light For Lead Asset
Samsung's Ontruzant Becomes First Trastuzumab Biosimilar Approved In EU
CHMP OKs Drugs For MS, Esophagitis, CMV & Hemophilia – And First EU Biosimilar Avastin
CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira
Radius's Tymlos Dawdles At CHMP, No EU Opinion Yet
Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Diurnal Nears Market With Novel Adrenal Insufficiency Products
Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel